Fungal diseases kill more than 1.5 million people per year, mostly in regions where neglected populations live [1]. This alarming number of deaths is part of a highly complex problem, since mortality alone does not give a complete picture of the fungal burden in different populations [2]. Indeed, several fungal diseases are associated with low mortality but directly linked to social exclusion and hospitalization. For instance, patients suffering from chromoblastomycosis manifest chronic and progressive cutaneous and subcutaneous lesions that can persist for decades [3]. Affected individuals may have significant mental health issues associated with this rare and chronic condition [4]. Fungal infections are the most diagnosed skin disease in Africa, especially in 1-to 5-years-old children [5], and these cutaneous mycoses are associated with social disapproval and psychological trauma, negatively affecting their performance in class [6]. These and other examples demonstrate that the burden of fungal infections is not restricted to mortality. Another way of measuring the impact of fungi on public health is to determine their overall burden of disease using the disability-adjusted life year (DALY). One DALY represents the loss of the equivalent of 1 year of full health [2]. However, with a few exceptions [5,7-10], DALY estimates are not available for most of the fungal diseases.Although fungal diseases are directly associated with neglected populations, they clearly also cause important public health problems in developed countries. For example, in the United States, individuals with diseases such as coccidioidomycosis experience 3 or more months of diminished mental and emotional health [11]. The economic impact of fungal diseases is remarkable. For example, in 2019, the US spent approximately USD 11.5 billion on serious fungal diseases, distributed into direct medical costs, productivity loss due to absenteeism, and premature deaths [12]. To give this number tangible dimensions, USD 11.5 billion represent 25% of the annual budget of the US National Institutes of Health (NIH) [13]. Even diseases such as onychomycosis cost over USD 2,000 per person affected in antifungal drug expenses alone [14]. In large part due to the complexity of fungi, including that they are eukaryotic organisms, the pace of generation of knowledge in the area of fighting fungal diseases is clearly slower than other areas [15]. There are no human licensed antifungal vaccines, and much has been discussed about the problems of antifungal therapies, which include high costs, emergence of antifungal resistance, significant toxicity, and limited number of antifungal drug classes [16]. It is likely that this complex scenario is the consequence of reduced funding for research and insufficient recognition of the impact of fungal diseases on public health by science policymakers and health authorities [17]. This scenario contrasts with the ever-changing epidemiology of fungal infections, which includes the emergence of highly lethal and drugresistant pa...